Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426) (Q35987124)

11 August 2017

Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426) (English)

1 reference

11 August 2017

1 reference

11

Southwest Oncology Group

1 reference

11 August 2017

2

Catherine M Tangen

1 reference

11 August 2017

A Oliver Sartor

1

1 reference

11 August 2017

Maha H A Hussain

3

1 reference

11 August 2017

Mario A Eisenberger

4

1 reference

11 August 2017

Minoti Parab

5

1 reference

11 August 2017

Joseph A Fontana

6

1 reference

11 August 2017

Robert A Chapman

7

1 reference

11 August 2017

Glenn M Mills

8

1 reference

11 August 2017

Derek Raghavan

9

1 reference

11 August 2017

E David Crawford

10

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

11 August 2017

1 reference

11 August 2017

112

1 reference

11 August 2017

11

1 reference

11 August 2017

2393-2400

1 reference

Association of African-American ethnic background with survival in men with metastatic prostate cancer

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

Estramustine phosphate withdrawal syndrome with dramatic pain relief

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3359896

Antiandrogen withdrawal in the treatment of hormone-relapsed prostate cancer: single institutional experience

24 September 2018

1 reference

12 December 2020

Response of metastatic breast cancer to tamoxifen withdrawal: report of a case

1 reference

12 December 2020

Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial

1 reference

12 December 2020

Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome

1 reference

12 December 2020

Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination Therapy

1 reference

12 December 2020

Withdrawal phenomenon with the antiandrogen casodex

1 reference

12 December 2020

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

1 reference

12 December 2020

Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol

1 reference

12 December 2020

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome

1 reference

12 December 2020

Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal

1 reference

12 December 2020

Antiandrogen withdrawal syndrome with nilutamide

1 reference

12 December 2020

Antiandrogen withdrawal syndrome with nilutamide

1 reference

12 December 2020

Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate

1 reference

12 December 2020

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

12 December 2020

Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes

1 reference

12 December 2020

Identifiers

DOI

10.1002/CNCR.23473

1 reference

release_rnnfey2jnvg23o4wwwr2i2vk4y

11 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rnnfey2jnvg23o4wwwr2i2vk4y

24 November 2022

mapped directly with Wikidata item

1 reference

11 August 2017

PubMed publication ID

18383517

1 reference